Skip to main content
SpringerLink
Log in

Drei vs. sechs Monate adjuvante Therapie beim Stadium-III-Kolonkarzinom

Three vs. six months of adjuvant therapy in stage III colon cancer

  • Journal Club
  • Published:
Die Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116

    Article  CAS  Google Scholar 

  2. Argiles G, Tabernero J, Labianca R et al (2020) Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1291–1305

    Article  CAS  Google Scholar 

  3. Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325–3348

    Article  Google Scholar 

  4. Yoshino T, Yamanaka T, Oki E et al (2019) Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol 5:1574–1581

    Article  Google Scholar 

  5. Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378:1177–1188

    Article  CAS  Google Scholar 

  6. Andre T, Meyerhardt J, Iveson T et al (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): Final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21:1620–1629

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Allgemein‑, Viszeral‑, Tumor- und Transplantationschirurgie, Universitätsklinikum Köln (AöR), Kerpener Str. 62, 50937, Köln, Deutschland

    Luca Fahrig &  Hakan Alakus

  2. Klinik I für Innere Medizin, Universitätsklinikum Köln, Köln, Deutschland

    Thomas Zander

Authors
  1. Luca Fahrig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Zander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hakan Alakus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hakan Alakus.

Ethics declarations

Interessenkonflikt

L. Fahrig, T. Zander und H. Alakus geben an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fahrig, L., Zander, T. & Alakus, H. Drei vs. sechs Monate adjuvante Therapie beim Stadium-III-Kolonkarzinom. Onkologie 28, 937–939 (2022). https://doi.org/10.1007/s00761-022-01215-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-022-01215-7

Search

Navigation